Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 120

1.

Predicting response to pembrolizumab in metastatic melanoma by a new personalization algorithm.

Tsur N, Kogan Y, Avizov-Khodak E, Vaeth D, Vogler N, Utikal J, Lotem M, Agur Z.

J Transl Med. 2019 Oct 7;17(1):338. doi: 10.1186/s12967-019-2081-2.

2.

Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study.

Robert C, Ribas A, Schachter J, Arance A, Grob JJ, Mortier L, Daud A, Carlino MS, McNeil CM, Lotem M, Larkin JMG, Lorigan P, Neyns B, Blank CU, Petrella TM, Hamid O, Su SC, Krepler C, Ibrahim N, Long GV.

Lancet Oncol. 2019 Sep;20(9):1239-1251. doi: 10.1016/S1470-2045(19)30388-2. Epub 2019 Jul 22.

PMID:
31345627
3.

Dabrafenib, trametinib and pembrolizumab or placebo in BRAF-mutant melanoma.

Ascierto PA, Ferrucci PF, Fisher R, Del Vecchio M, Atkinson V, Schmidt H, Schachter J, Queirolo P, Long GV, Di Giacomo AM, Svane IM, Lotem M, Bar-Sela G, Couture F, Mookerjee B, Ghori R, Ibrahim N, Moreno BH, Ribas A.

Nat Med. 2019 Jun;25(6):941-946. doi: 10.1038/s41591-019-0448-9. Epub 2019 Jun 6.

PMID:
31171878
4.

BASELINE TSH LEVEL IS ASSOCIATED WITH RISK OF ANTI-PD-1-INDUCED THYROID DYSFUNCTION.

Pollack RM, Kagan M, Lotem M, Dresner-Pollak R.

Endocr Pract. 2019 Aug;25(8):824-829. doi: 10.4158/EP-2018-0472. Epub 2019 Apr 23.

PMID:
31013164
5.

Tumor mutational burden and response to programmed cell death protein 1 inhibitors in a case series of patients with metastatic desmoplastic melanoma.

Boussemart L, Johnson A, Schrock AB, Pal SK, Frampton GM, Fabrizio D, Chalmers Z, Lotem M, Gibney G, Russell J, Chmielowski B, Ross JS, Stephens PJ, Miller VA, Ali SM.

J Am Acad Dermatol. 2019 Jun;80(6):1780-1782. doi: 10.1016/j.jaad.2018.12.020. Epub 2018 Dec 18. No abstract available.

6.

Combined Expression of Genetic Adjuvants Via mRNA Electroporation Exerts Multiple Immunostimulatory Effects on Antitumor T Cells.

Weinstein-Marom H, Levin N, Pato A, Shmuel N, Sharabi-Nov A, Peretz T, Eisenberg G, Lotem M, Itzhaki O, Besser MJ, Gross G.

J Immunother. 2019 Feb/Mar;42(2):43-50. doi: 10.1097/CJI.0000000000000252.

PMID:
30489430
7.

Potent Activation of Human T Cells by mRNA Encoding Constitutively Active CD40.

Levin N, Weinstein-Marom H, Pato A, Itzhaki O, Besser MJ, Eisenberg G, Peretz T, Lotem M, Gross G.

J Immunol. 2018 Nov 15;201(10):2959-2968. doi: 10.4049/jimmunol.1701725. Epub 2018 Oct 10.

8.

Combined Analysis of Antigen Presentation and T-cell Recognition Reveals Restricted Immune Responses in Melanoma.

Kalaora S, Wolf Y, Feferman T, Barnea E, Greenstein E, Reshef D, Tirosh I, Reuben A, Patkar S, Levy R, Quinkhardt J, Omokoko T, Qutob N, Golani O, Zhang J, Mao X, Song X, Bernatchez C, Haymaker C, Forget MA, Creasy C, Greenberg P, Carter BW, Cooper ZA, Rosenberg SA, Lotem M, Sahin U, Shakhar G, Ruppin E, Wargo JA, Friedman N, Admon A, Samuels Y.

Cancer Discov. 2018 Nov;8(11):1366-1375. doi: 10.1158/2159-8290.CD-17-1418. Epub 2018 Sep 12.

9.

Exploring the potential of mucin 13 (MUC13) as a biomarker for carcinomas and other diseases.

Filippou PS, Ren AH, Korbakis D, Dimitrakopoulos L, Soosaipillai A, Barak V, Frenkel S, Pe'er J, Lotem M, Merims S, Molina R, Blasutig I, Bogdanos DP, Diamandis EP.

Clin Chem Lab Med. 2018 Oct 25;56(11):1945-1953. doi: 10.1515/cclm-2018-0139.

PMID:
29768245
10.

Neurologic complications of immune checkpoint inhibitors.

Fellner A, Makranz C, Lotem M, Bokstein F, Taliansky A, Rosenberg S, Blumenthal DT, Mandel J, Fichman S, Kogan E, Steiner I, Siegal T, Lossos A, Yust-Katz S.

J Neurooncol. 2018 May;137(3):601-609. doi: 10.1007/s11060-018-2752-5. Epub 2018 Jan 13.

PMID:
29332184
11.

Soluble SLAMF6 Receptor Induces Strong CD8+ T-cell Effector Function and Improves Anti-Melanoma Activity In Vivo.

Eisenberg G, Engelstein R, Geiger-Maor A, Hajaj E, Merims S, Frankenburg S, Uzana R, Rutenberg A, Machlenkin A, Frei G, Peretz T, Lotem M.

Cancer Immunol Res. 2018 Feb;6(2):127-138. doi: 10.1158/2326-6066.CIR-17-0383. Epub 2018 Jan 5.

12.

Predictors of responses to immune checkpoint blockade in advanced melanoma.

Jacquelot N, Roberti MP, Enot DP, Rusakiewicz S, Ternès N, Jegou S, Woods DM, Sodré AL, Hansen M, Meirow Y, Sade-Feldman M, Burra A, Kwek SS, Flament C, Messaoudene M, Duong CPM, Chen L, Kwon BS, Anderson AC, Kuchroo VK, Weide B, Aubin F, Borg C, Dalle S, Beatrix O, Ayyoub M, Balme B, Tomasic G, Di Giacomo AM, Maio M, Schadendorf D, Melero I, Dréno B, Khammari A, Dummer R, Levesque M, Koguchi Y, Fong L, Lotem M, Baniyash M, Schmidt H, Svane IM, Kroemer G, Marabelle A, Michiels S, Cavalcanti A, Smyth MJ, Weber JS, Eggermont AM, Zitvogel L.

Nat Commun. 2017 Sep 19;8(1):592. doi: 10.1038/s41467-017-00608-2.

13.

Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006).

Schachter J, Ribas A, Long GV, Arance A, Grob JJ, Mortier L, Daud A, Carlino MS, McNeil C, Lotem M, Larkin J, Lorigan P, Neyns B, Blank C, Petrella TM, Hamid O, Zhou H, Ebbinghaus S, Ibrahim N, Robert C.

Lancet. 2017 Oct 21;390(10105):1853-1862. doi: 10.1016/S0140-6736(17)31601-X. Epub 2017 Aug 16.

PMID:
28822576
14.

Phenotype-based variation as a biomarker of sensitivity to molecularly targeted therapy in melanoma.

Senses KM, Ghasemi M, Akbar MW, Isbilen M, Fallacara AL, Frankenburg S, Schenone S, Lotem M, Botta M, Gure AO.

Medchemcomm. 2017 Jan 1;8(1):88-95. doi: 10.1039/C6MD00466K. Epub 2016 Oct 27.

15.

Treatment inferred from mutations identified using massive parallel sequencing leads to clinical benefit in some heavily pretreated cancer patients.

Zick A, Peretz T, Lotem M, Hubert A, Katz D, Temper M, Rottenberg Y, Uziely B, Nechushtan H, Meirovitz A, Sonnenblick A, Sapir E, Edelman D, Goldberg Y, Lossos A, Rosenberg S, Fried I, Finklstein R, Pikarsky E, Goldshmidt H.

Medicine (Baltimore). 2017 May;96(20):e6931. doi: 10.1097/MD.0000000000006931.

16.

Adoptive cell therapy: past, present and future.

Cohen JE, Merims S, Frank S, Engelstein R, Peretz T, Lotem M.

Immunotherapy. 2017 Jan;9(2):183-196. doi: 10.2217/imt-2016-0112. Review.

PMID:
28128715
17.

Organizing pneumonia following treatment with pembrolizumab for metastatic malignant melanoma - A case report.

Kuint R, Lotem M, Neuman T, Bekker-Milovanov E, Abutbul A, Laxer U, Berkman N, Fridlender ZG.

Respir Med Case Rep. 2017 Jan 12;20:95-97. doi: 10.1016/j.rmcr.2017.01.003. eCollection 2017.

18.

Spontaneous Activation of Antigen-presenting Cells by Genes Encoding Truncated Homo-Oligomerizing Derivatives of CD40.

Levin N, Pato A, Cafri G, Eisenberg G, Peretz T, Margalit A, Lotem M, Gross G.

J Immunother. 2017 Feb/Mar;40(2):39-50. doi: 10.1097/CJI.0000000000000150.

PMID:
28005579
19.

Clinical Significance of Circulating CD33+CD11b+HLA-DR- Myeloid Cells in Patients with Stage IV Melanoma Treated with Ipilimumab.

Sade-Feldman M, Kanterman J, Klieger Y, Ish-Shalom E, Olga M, Saragovi A, Shtainberg H, Lotem M, Baniyash M.

Clin Cancer Res. 2016 Dec 1;22(23):5661-5672. Epub 2016 May 13.

20.

Immune Monitoring of Patients Treated With a Whole-Cell Melanoma Vaccine Engineered to Express 4-1BBL.

Engelstein R, Merims S, Eisenberg G, Cohen J, Frank S, Hamburger T, Frankenburg S, Ron I, Isacson R, Grenader T, Steinberg H, Cohen CJ, Peretz T, Lotem M.

J Immunother. 2016 Oct;39(8):321-8. doi: 10.1097/CJI.0000000000000138.

PMID:
27564312
21.

Adjuvant Autologous Melanoma Vaccine for Macroscopic Stage III Disease: Survival, Biomarkers, and Improved Response to CTLA-4 Blockade.

Lotem M, Merims S, Frank S, Hamburger T, Nissan A, Kadouri L, Cohen J, Straussman R, Eisenberg G, Frankenburg S, Carmon E, Alaiyan B, Shneibaum S, Ozge Ayyildiz Z, Isbilen M, Mert Senses K, Ron I, Steinberg H, Smith Y, Shiloni E, Gure AO, Peretz T.

J Immunol Res. 2016;2016:8121985. doi: 10.1155/2016/8121985. Epub 2016 May 18.

22.

Membrane-attached Cytokines Expressed by mRNA Electroporation Act as Potent T-Cell Adjuvants.

Weinstein-Marom H, Pato A, Levin N, Susid K, Itzhaki O, Besser MJ, Peretz T, Margalit A, Lotem M, Gross G.

J Immunother. 2016 Feb-Mar;39(2):60-70. doi: 10.1097/CJI.0000000000000109.

PMID:
26849075
23.

Widespread morbilliform rash due to sorafenib or vemurafenib treatment for advanced cancer; experience of a tertiary dermato-oncology clinic.

Ollech A, Stemmer SM, Merims S, Lotem M, Popovtzer A, Hendler D, Hodak E, Didkovsky E, Amitay-Laish I.

Int J Dermatol. 2016 Apr;55(4):473-8. doi: 10.1111/ijd.13153. Epub 2016 Jan 29.

PMID:
26825962
24.

Assessing Response to New Treatments and Prognosis in Melanoma Patients, by the Biomarker S-100β.

Barak V, Leibovici V, Peretz T, Kalichman I, Lotem M, Merims S.

Anticancer Res. 2015 Dec;35(12):6755-60.

PMID:
26637892
25.

Messenger RNA encoding constitutively active Toll-like receptor 4 enhances effector functions of human T cells.

Pato A, Eisenberg G, Machlenkin A, Margalit A, Cafri G, Frankenburg S, Merims S, Peretz T, Lotem M, Gross G.

Clin Exp Immunol. 2015 Nov;182(2):220-9. doi: 10.1111/cei.12688. Epub 2015 Aug 28.

26.

Pembrolizumab versus Ipilimumab in Advanced Melanoma.

Robert C, Schachter J, Long GV, Arance A, Grob JJ, Mortier L, Daud A, Carlino MS, McNeil C, Lotem M, Larkin J, Lorigan P, Neyns B, Blank CU, Hamid O, Mateus C, Shapira-Frommer R, Kosh M, Zhou H, Ibrahim N, Ebbinghaus S, Ribas A; KEYNOTE-006 investigators.

N Engl J Med. 2015 Jun 25;372(26):2521-32. doi: 10.1056/NEJMoa1503093. Epub 2015 Apr 19.

27.

Human T cell crosstalk is induced by tumor membrane transfer.

Uzana R, Eisenberg G, Merims S, Frankenburg S, Pato A, Yefenof E, Engelstein R, Peretz T, Machlenkin A, Lotem M.

PLoS One. 2015 Feb 11;10(2):e0118244. doi: 10.1371/journal.pone.0118244. eCollection 2015.

28.

Pathways and therapeutic targets in melanoma.

Shtivelman E, Davies MQ, Hwu P, Yang J, Lotem M, Oren M, Flaherty KT, Fisher DE.

Oncotarget. 2014 Apr 15;5(7):1701-52. Review.

29.

A new role of vemurafenib as a neoadjuvant treatment of axillary and brain melanoma metastases.

Melnik I, Lotem M, Yoffe B.

Case Rep Oncol Med. 2013;2013:794239. doi: 10.1155/2013/794239. Epub 2013 Dec 23.

30.

Ocular melanoma metastasizing to intra-abdominal lymph nodes.

Aranovich D, Meir K, Lotem MM, Appelbaum L, Merhav H.

Case Rep Surg. 2013;2013:534730. doi: 10.1155/2013/534730. Epub 2013 May 16.

31.

Imprinting of lymphocytes with melanoma antigens acquired by trogocytosis facilitates identification of tumor-reactive T cells.

Eisenberg G, Uzana R, Pato A, Frankenburg S, Merims S, Yefenof E, Ferrone S, Peretz T, Machlenkin A, Lotem M.

J Immunol. 2013 Jun 1;190(11):5856-65. doi: 10.4049/jimmunol.1202879. Epub 2013 Apr 26.

32.

Safety and efficacy of 188-rhenium-labeled antibody to melanin in patients with metastatic melanoma.

Klein M, Lotem M, Peretz T, Zwas ST, Mizrachi S, Liberman Y, Chisin R, Schachter J, Ron IG, Iosilevsky G, Kennedy JA, Revskaya E, de Kater AW, Banaga E, Klutzaritz V, Friedmann N, Galun E, Denardo GL, Denardo SJ, Casadevall A, Dadachova E, Thornton GB.

J Skin Cancer. 2013;2013:828329. doi: 10.1155/2013/828329. Epub 2013 Jan 10.

33.

[Ctla-4 blockade: a new hope for the immunotherapy of malignant melanoma].

Lotem M, Merims S, Frank S, Ospovat I, Peretz T.

Harefuah. 2012 Oct;151(10):585-8, 604. Review. Hebrew.

PMID:
23316667
34.

Extracellular matrix constituents interfere with Newcastle disease virus spread in solid tissue and diminish its potential oncolytic activity.

Yaacov B, Lazar I, Tayeb S, Frank S, Izhar U, Lotem M, Perlman R, Ben-Yehuda D, Zakay-Rones Z, Panet A.

J Gen Virol. 2012 Aug;93(Pt 8):1664-72. doi: 10.1099/vir.0.043281-0. Epub 2012 May 23.

PMID:
22622327
35.

The clinical effect of the inhibitor of apopotosis protein livin in melanoma.

Lazar I, Perlman R, Lotem M, Peretz T, Ben-Yehuda D, Kadouri L.

Oncology. 2012;82(4):197-204. doi: 10.1159/000334234. Epub 2012 Mar 22.

PMID:
22441029
36.

Trogocytosis is a gateway to characterize functional diversity in melanoma-specific CD8+ T cell clones.

Uzana R, Eisenberg G, Sagi Y, Frankenburg S, Merims S, Amariglio N, Yefenof E, Peretz T, Machlenkin A, Lotem M.

J Immunol. 2012 Jan 15;188(2):632-40. doi: 10.4049/jimmunol.1101429. Epub 2011 Dec 7.

37.

HLA-B35 correlates with a favorable outcome following adjuvant administration of an HLA-matched allogeneic melanoma vaccine.

Lotem M, Kadouri L, Merims S, Ospovat I, Nissan A, Ron I, Frankenburg S, Machlenkin A, Israel S, Steinberg H, Hamburger T, Peretz T.

Tissue Antigens. 2011 Sep;78(3):203-7. doi: 10.1111/j.1399-0039.2011.01709.x. Epub 2011 Jun 7.

PMID:
21644933
38.

Ipilimumab plus dacarbazine for previously untreated metastatic melanoma.

Robert C, Thomas L, Bondarenko I, O'Day S, Weber J, Garbe C, Lebbe C, Baurain JF, Testori A, Grob JJ, Davidson N, Richards J, Maio M, Hauschild A, Miller WH Jr, Gascon P, Lotem M, Harmankaya K, Ibrahim R, Francis S, Chen TT, Humphrey R, Hoos A, Wolchok JD.

N Engl J Med. 2011 Jun 30;364(26):2517-26. doi: 10.1056/NEJMoa1104621. Epub 2011 Jun 5.

39.

Transcutaneous immunization with hydrophilic recombinant gp100 protein induces antigen-specific cellular immune response.

Eisenberg G, Machlenkin A, Frankenburg S, Mansura A, Pitcovski J, Yefenof E, Peretz T, Lotem M.

Cell Immunol. 2010;266(1):98-103. doi: 10.1016/j.cellimm.2010.09.003. Epub 2010 Sep 18.

40.

The oncolytic activity of Newcastle disease virus NDV-HUJ on chemoresistant primary melanoma cells is dependent on the proapoptotic activity of the inhibitor of apoptosis protein Livin.

Lazar I, Yaacov B, Shiloach T, Eliahoo E, Kadouri L, Lotem M, Perlman R, Zakay-Rones Z, Panet A, Ben-Yehuda D.

J Virol. 2010 Jan;84(1):639-46. doi: 10.1128/JVI.00401-09.

41.

Autologous melanoma vaccine induces antitumor and self-reactive immune responses that affect patient survival and depend on MHC class II expression on vaccine cells.

Lotem M, Machlenkin A, Hamburger T, Nissan A, Kadouri L, Frankenburg S, Gimmon Z, Elias O, David IB, Kuznetz A, Shiloni E, Peretz T.

Clin Cancer Res. 2009 Aug 1;15(15):4968-77. doi: 10.1158/1078-0432.CCR-08-3320. Epub 2009 Jul 14.

42.

Uveal melanoma cell-based vaccines express MHC II molecules that traffic via the endocytic and secretory pathways and activate CD8+ cytotoxic, tumor-specific T cells.

Bosch JJ, Iheagwara UK, Reid S, Srivastava MK, Wolf J, Lotem M, Ksander BR, Ostrand-Rosenberg S.

Cancer Immunol Immunother. 2010 Jan;59(1):103-12. doi: 10.1007/s00262-009-0729-0. Epub 2009 Jun 26.

43.

Long-term survival of uveal melanoma patients after surgery for liver metastases.

Frenkel S, Nir I, Hendler K, Lotem M, Eid A, Jurim O, Pe'er J.

Br J Ophthalmol. 2009 Aug;93(8):1042-6. doi: 10.1136/bjo.2008.153684. Epub 2009 May 7.

PMID:
19429579
44.

Absence of founder BRCA1 and BRCA2 mutations in cutaneous malignant melanoma patients of Ashkenazi origin.

Kadouri L, Temper M, Grenader T, Abeliovich D, Hamburger T, Peretz T, Lotem M.

Fam Cancer. 2009;8(1):29-32. doi: 10.1007/s10689-008-9206-8. Epub 2008 Aug 5.

PMID:
18679827
45.

Metastatic malignant melanoma involving the parotid lymph node region: a clinicopathologic report of 5 cases.

Gross M, Maly B, Maly A, Lotem M, Eliashar R.

J Oral Maxillofac Surg. 2008 Apr;66(4):809-13. doi: 10.1016/j.joms.2006.10.065. No abstract available.

PMID:
18355611
46.

Capture of tumor cell membranes by trogocytosis facilitates detection and isolation of tumor-specific functional CTLs.

Machlenkin A, Uzana R, Frankenburg S, Eisenberg G, Eisenbach L, Pitcovski J, Gorodetsky R, Nissan A, Peretz T, Lotem M.

Cancer Res. 2008 Mar 15;68(6):2006-13. doi: 10.1158/0008-5472.CAN-07-3119.

47.

A melanoma multiepitope polypeptide induces specific CD8+ T-cell response.

Levy A, Pitcovski J, Frankenburg S, Elias O, Altuvia Y, Margalit H, Peretz T, Golenser J, Lotem M.

Cell Immunol. 2007 Nov-Dec;250(1-2):24-30. doi: 10.1016/j.cellimm.2008.01.001. Epub 2008 Feb 13.

48.

[Parents' risk perception and analysis of children's injuries scenarios from cold fat removers].

Lotem MH, Klein M, Haim LS, Raanan R, Pinkas AE, Findling LE.

Harefuah. 2007 Jul;146(7):523-8, 575, 574. Hebrew.

PMID:
17803165
49.

Viral carcinogenesis in skin cancer.

Molho-Pessach V, Lotem M.

Curr Probl Dermatol. 2007;35:39-51. doi: 10.1159/000106409. Review.

PMID:
17641489
50.

Ultraviolet radiation and cutaneous carcinogenesis.

Molho-Pessach V, Lotem M.

Curr Probl Dermatol. 2007;35:14-27. doi: 10.1159/000106407. Review.

PMID:
17641487

Supplemental Content

Support Center